Biological
Hib-MenCY-TT vaccine clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 2
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2003 (2)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
- Phase 3
- 2
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Pediarix (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (1)
Studies
Open first, then newest update. How each study uses Hib-MenCY-TT vaccine is read from its arms, and is right about nine times in ten.
Testing it · 5
- Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of AgeCompletedPhase 3GlaxoSmithKlineNCT01978093Written as Hib-MenCY-TT (MenHibrix®)
- 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of AgeCompletedPhase 2GlaxoSmithKlineNCT00129116Written as Hib-MenCY-TT vaccine
- Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) VaccineCompletedPhase 2GlaxoSmithKlineNCT00127855Written as Hib-MenCY-TT vaccine (MenHibrix)
- Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate VaccinesCompletedPhase 2GlaxoSmithKlineNCT00134719Written as MenHibrix (Hib-MenCY-TT)
- Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIBCompletedPhase 3GlaxoSmithKlineNCT00359983Written as MenHibrix (Hib-MenCY-TT)